Ing Groep Nv Biomarin Pharmaceutical Inc Transaction History

Ing Groep Nv

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	BUY	$76.22 - $98.51 $16 Million - $20.7 Million	210,000 New	210,000 $20.2 Million
Q2 2019 Aug 12, 2019	SELL	$80.35 - $93.9 $467,154 - $545,934	-5,814 Closed	0 $0
Q1 2019 May 13, 2019	SELL	$84.2 - $98.62 $259,083 - $303,453	-3,077 Reduced 34.61%	5,814 $516,000
Q4 2018 Feb 13, 2019	SELL	$80.14 - $106.07 $292,430 - $387,049	-3,649 Reduced 29.1%	8,891 $757,000
Q3 2018 Nov 06, 2018	BUY	$93.92 - $105.72 $826,965 - $930,864	8,805 Added 235.74%	12,540 $1.22 Million
Q2 2018 Aug 10, 2018	BUY	$76.01 - $99.03 $7,601 - $9,903	100 Added 2.75%	3,735 $352,000
Q1 2018 May 07, 2018	SELL	$77.67 - $92.63 $84,427 - $100,688	-1,087 Reduced 23.02%	3,635 $295,000
Q4 2017 Feb 06, 2018	SELL	$80.76 - $95.13 $58,793 - $69,254	-728 Reduced 13.36%	4,722 $421,000
Q3 2017 Nov 08, 2017	BUY	$80.6 - $94.95 $439,269 - $517,477	5,450	5,450 $507,000

635

178M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Ing Groep Nv, based on Form 13F filings with the SEC.

Stay updated on Ing Groep Nv with notifications on news.